Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Terhalose (natural disaccharide), 1.65?g twice a day (3.3 g/day) for 3 months, in opaque sachet form. Intervention 2: Control group: Sucrose, 1.65?g twice a day (3.
Sponsors
National Institute for Medical Research Development
Eligibility
Sex/Gender
All
Age
35 Years to 85 Years
Inclusion criteria
Inclusion criteria: Male or female patients aged between 35 and 85 years Patients with non-insulin-dependent diabetes mellitus in a stable condition.
Exclusion criteria
Exclusion criteria: Patients with type 1, type 2, or secondary diabetes receiving insulin therapy. Patients with renal dysfunction (eGFR less than 30 ml/min). Patients with severe liver dysfunction or cirrhosis. Patients regularly receiving oral or injectable corticosteroids. Patients who were pregnant or nursing or wished to conceive. Patients participating in this study will be excluded from the study if they need insulin. Patients who used a-Glucosidase Inhibitors such as acarbose will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HOMA-IR alterations. Timepoint: At the beginning and end of the intervention trial (Day 0 and week 12). Method of measurement: HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose (FPG). Timepoint: Baseline and week 12. Method of measurement: Enzymatic assay.;Fasting insulin. Timepoint: Baseline and week 12. Method of measurement: Immunoassay.;HbA1c. Timepoint: Baseline and week 12. Method of measurement: chromatography.;C peptide. Timepoint: Baseline and week 12. Method of measurement: Immunoassay.;Hs-CRP. Timepoint: Baseline and week 12. Method of measurement: Turbidimetric. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Sahebkar
Mashhad University of Medical Sciences
Outcome results
None listed